Positive Phase 3 results from Moderna and Merck’s intismeran autogene, a personalized mRNA neoantigen vaccine combined with Keytruda, represent the main catalyst for trader sentiment. The INTerpath-001 trial in 1,137 high-risk melanoma patients showed a 42% reduction in recurrence or death risk versus Keytruda alone at two years (82.2% vs. 70% recurrence-free), with durable benefit confirmed in longer follow-up. Companies are now engaging regulators and preparing a U.S. filing, with analysts projecting possible approval and 2027 launch. Key variables include the FDA’s handling of the combination regimen, individualized manufacturing timelines of roughly six weeks, and whether survival data or confirmatory trials accelerate or delay clearance. Other candidates remain earlier-stage.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日1H6H1D7D30DALL
View resolved

外部リンクに注意してください。
外部リンクに注意してください。
よくある質問